Clinical trials - Press Releases

Date	Title	Company
14-Jun-2022	Novotech's APAC and USA Leadership Teams at BIO 2022	Novotech Health Holdings Pte Ltd
14-Jun-2022	mdgroup appoints LaQuinta Jernigan as Chief Operating Officer	mdgroup
14-Jun-2022	PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications	PureTech
14-Jun-2022	Andaman7 argues case for greater patient mediated research at HIMSS European Health Conference 2022	Andaman7
14-Jun-2022	Precision Cancer Diagnostic Test market is projected to grow at a CAGR of 15% By 2032	Visiongain Reports Limited
13-Jun-2022	Global plasma protein therapeutics market is projected to reach a market value of US$59.58 billion in 2032.	Visiongain Reports Limited
10-Jun-2022	Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting	Nordic Nanovector
10-Jun-2022	Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market is projected to reach US$56,737.2 Million in 2031: Visiongain Research Inc	Visiongain
09-Jun-2022	mdgroup recognised as one of the UK's fastest-growing private companies	mdgroup
08-Jun-2022	First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)	HMNC Brain Health
08-Jun-2022	Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial	AstraZeneca
07-Jun-2022	SCRS Global Impact Partner Program Grows with Addition of Clinerion	Clinerion Ltd.
07-Jun-2022	Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus	Arbutus Biopharma Corporation
07-Jun-2022	Nouscom Announces Positive Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR / MSI-H Solid Tumors, at ASCO 2022	Nouscom
07-Jun-2022	Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022	Transgene
07-Jun-2022	Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022	Enterome
07-Jun-2022	Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma	Janssen
07-Jun-2022	Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment	Nordic Nanovector
02-Jun-2022	Novotech Sponsors Pre-ASCO China Summit Panels on Early Phase Oncology Trials, Regulatory Strategy for China and US	Novotech Health Holdings
01-Jun-2022	Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism	Amolyt Pharma